These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 38920074)

  • 1. Significance of Ribonucleoside-diphosphate Reductase Subunit M2 in Lung Adenocarcinoma.
    Wang XJ; Huo YX; Yang PJ; Gao J; Hu WD
    Curr Gene Ther; 2024 Jun; ():. PubMed ID: 38920074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High expression of RRM2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma.
    Jin CY; Du L; Nuerlan AH; Wang XL; Yang YW; Guo R
    Aging (Albany NY); 2020 Dec; 13(3):3518-3535. PubMed ID: 33411689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Independent prognostic implications of
    Ma C; Luo H; Cao J; Gao C; Fa X; Wang G
    J Cancer; 2020; 11(23):7009-7022. PubMed ID: 33123291
    [No Abstract]   [Full Text] [Related]  

  • 4. RRM2 silencing suppresses malignant phenotype and enhances radiosensitivity via activating cGAS/STING signaling pathway in lung adenocarcinoma.
    Jiang X; Li Y; Zhang N; Gao Y; Han L; Li S; Li J; Liu X; Gong Y; Xie C
    Cell Biosci; 2021 Apr; 11(1):74. PubMed ID: 33858512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-202-3p inhibits the proliferation and metastasis of lung adenocarcinoma cells by targeting RRM2.
    Cao X; Xue F; Chen H; Shen L; Yuan X; Yu Y; Zong Y; Zhong L; Huang F
    Ann Transl Med; 2022 Dec; 10(24):1374. PubMed ID: 36660663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of critical ferroptosis regulators in lung adenocarcinoma that RRM2 facilitates tumor immune infiltration by inhibiting ferroptotic death.
    Tang B; Xu W; Wang Y; Zhu J; Wang H; Tu J; Weng Q; Kong C; Yang Y; Qiu R; Zhao Z; Xu M; Ji J
    Clin Immunol; 2021 Nov; 232():108872. PubMed ID: 34648954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and validation of a ferroptosis-related gene to predict survival outcomes and the immune microenvironment in lung adenocarcinoma.
    Deng B; Xiang J; Liang Z; Luo L
    Cancer Cell Int; 2022 Sep; 22(1):292. PubMed ID: 36153508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. E2F8 exerts cancer-promoting effects by transcriptionally activating RRM2 and E2F8 knockdown synergizes with WEE1 inhibition in suppressing lung adenocarcinoma.
    Liu K; Wang L; Lou Z; Guo L; Xu Y; Qi H; Fang Z; Mei L; Chen X; Zhang X; Shao J; Xiang X
    Biochem Pharmacol; 2023 Dec; 218():115854. PubMed ID: 37863324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of the immune microenvironment associated with RRM2 expression and its application to PD-L1/PD-1 inhibitors in lung adenocarcinoma.
    Lee SK; Hwang Y; Han JH; Haam S; Lee HW; Koh YW
    Am J Cancer Res; 2023; 13(11):5443-5454. PubMed ID: 38058821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive bioinformatics analysis of ribonucleoside diphosphate reductase subunit M2(RRM2) gene correlates with prognosis and tumor immunotherapy in pan-cancer.
    Wu L; Yin L; Ma L; Yang J; Yang F; Sun B; Nianzeng X
    Aging (Albany NY); 2022 Oct; 14(19):7890-7905. PubMed ID: 36202136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment.
    Fisher SB; Patel SH; Bagci P; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Maithel SK
    Cancer; 2013 Jan; 119(2):445-53. PubMed ID: 22569992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting ribonucleotide reductase M2 subunit by small interfering RNA exerts anti-oncogenic effects in gastric adenocarcinoma.
    Kang W; Tong JH; Chan AW; Zhao J; Wang S; Dong Y; Sin FM; Yeung S; Cheng AS; Yu J; To K
    Oncol Rep; 2014 Jun; 31(6):2579-86. PubMed ID: 24756820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ribonucleotide reductase M2 subunit silencing suppresses tumorigenesis in pancreatic cancer via inactivation of PI3K/AKT/mTOR pathway.
    Shan J; Wang Z; Mo Q; Long J; Fan Y; Cheng L; Zhang T; Liu X; Wang X
    Pancreatology; 2022 Apr; 22(3):401-413. PubMed ID: 35300916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers.
    Huang Y; Liu X; Wang YH; Yeh SD; Chen CL; Nelson RA; Chu P; Wilson T; Yen Y
    Urol Oncol; 2014 Jan; 32(1):51.e9-19. PubMed ID: 24360663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ribonucleotide reductase M2 subunit expression and prognostic value in nasopharyngeal carcinoma.
    Han P; Lin ZR; Xu LH; Zhong Q; Zhu XF; Liang FY; Cai Q; Huang XM; Zeng MS
    Mol Med Rep; 2015 Jul; 12(1):401-9. PubMed ID: 25695839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical role for ribonucleoside-diphosphate reductase subunit M2 in ALV-J-induced activation of Wnt/β-catenin signaling via interaction with P27.
    Tang S; Leng M; Tan C; Zhu L; Pang Y; Zhang X; Chang YF; Lin W
    J Virol; 2023 Aug; 97(8):e0026723. PubMed ID: 37582207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging roles of the ribonucleotide reductase M2 in colorectal cancer and ultraviolet-induced DNA damage repair.
    Lu AG; Feng H; Wang PX; Han DP; Chen XH; Zheng MH
    World J Gastroenterol; 2012 Sep; 18(34):4704-13. PubMed ID: 23002339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Over-expression of RRM2 predicts adverse prognosis correlated with immune infiltrates: A potential biomarker for hepatocellular carcinoma.
    Qin Z; Xie B; Qian J; Ma X; Zhang L; Wei J; Wang Z; Fan L; Zhu Z; Qian Z; Yin H; Zhu F; Tan Y
    Front Oncol; 2023; 13():1144269. PubMed ID: 37056349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
    Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
    BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy.
    Rahman MA; Amin AR; Wang D; Koenig L; Nannapaneni S; Chen Z; Wang Z; Sica G; Deng X; Chen ZG; Shin DM
    Clin Cancer Res; 2013 Jul; 19(13):3416-28. PubMed ID: 23719266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.